The table below shows Cullinan Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$46.05M
-$43.16M
-$38.25M
-$51.00M
-$21.91M
-$1.51M
Capital expenditure
-
-
$0.00
$159.00K
$0.00
-
Investing cash flow
$32.41M
$36.80M
$12.96M
$15.18M
$34.71M
-$137.73M
Dividends paid
-
-
-
-
-
CGEM operating cash flow (10-K history)
Cullinan Therapeutics, Inc. reported operating cash flow of -$175.75M for fiscal year 2025. That is down 21.0% from -$145.30M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$29.77M (FY 2020) to -$175.75M. Figures come from the company's audited annual reports as filed with the SEC.
